A trial to find out how useful a blood test is to monitor people with breast cancer (TRAK-ER)

This trial is looking at whether a blood test can find cancer that has come back before doctors can see it on a scan. It is also looking at whether treatment with palbociclib combined with fulvestrant is better than standard hormone treatment for these people.

The trial is open to people:

• with breast cancer that is oestrogen positive (ER positive) and doesn’t have the HER2 protein (HER2 negative)

• who have had treatment and are at a high risk of the cancer coming back